Arkolith/Insider Trading/AKYA/Form 4

Bamford Pascal

Chief Clinical OfficerAkoya Biosciences, Inc. (AKYA) · full profile →Form 4 · filed Jul 10, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
2 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 8, 2025Other(J)196K——0
Jul 8, 2025Other(J)9K——196K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 8, 2025Other(J)50K—$00
Jul 8, 2025Other(J)15K—$00
Jul 8, 2025Other(J)25K—$00
Jul 8, 2025Other(J)150K—$00

Transaction Codes

J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-25-012727) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML